diagnostics

Labs face a growing compliance burden and increased uncertainty due to new regulations surrounding laboratory-developed tests (LDTs). The U.S. FDA’s final rule and Supreme Court’s recent decision to overturn the Chevron doctrine are creating a complex regulatory environment that challenges the ability of public health labs to rapidly respond to emerging pathogens. This article explores the implications of these changes and more.

Characterizing biomarkers in lung cancer tumors is challenging due to the high risks associated with tissue retrieval. Liquid biopsy offers a safer alternative but requires highly sensitive and precise methods to generate robust results from minimal genetic material. In this video, Dr. Schuuring of the University Medical Center Groningen discusses how Droplet Digital PCR (ddPCR) is used in his laboratories and why this technology has become critical for his research.

Whether you are part of a small academic lab or a multinational corporation, upgrading to a new quantitative PCR (qPCR) system can be both exciting and daunting. How will the new system perform compared to your current platform? Will your existing workflows translate smoothly? Read on to learn about our recent bridging study for users considering upgrading to the new CFX Opus Real-Time PCR System.

No patient who has survived cancer wants to hear that they’ve relapsed. But hearing it sooner rather than later can dramatically increase the chances of finding a successful, potentially life-saving treatment. Using next-generation sequencing and Droplet Digital PCR, researchers at the University of Uppsala aim to detect relapse by monitoring patient-specific biomarkers. Read about their ongoing clinical study.

Bio-Rad is proud to introduce our new RT-PCR testing kits for COVID-19. These all-in-one kits are designed for sensitive, specific detection of SARS-CoV-2 alone, or simultaneous detection of SARS-CoV-2, influenza A, and influenza B. Read on to learn about each kit’s features.